title: How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
authors.affiliation: Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and Carsten Denkert, German Breast Group, Neu-Isenburg, Germany; and Charité University Hospital, Berlin, Germany.
authors.forename: Sibylle
authors.initials: S
authors.lastname: Loibl
authors.affiliation: Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and Carsten Denkert, German Breast Group, Neu-Isenburg, Germany; and Charité University Hospital, Berlin, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Denkert
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D020360:Neoadjuvant Therapy; D018365:Neoplasm, Residual; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases